EU CDK 4/6 Inhibitor Safety Info Update Goes Ahead
Product Info Warns Of Rare But Severe Pulmonary Side Effects
The EU product information for Ibrance, Verzenios and Kisqali is being updated to include interstitial lung disease and pneumonitis. The change has already been implemented in the US.
You may also be interested in...
Survival Data Boost Lilly & Novartis’s CDK4/6 Assault On Pfizer’s Ibrance In Metastatic Breast Cancer
Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.